Notifications Bell

Stocks mixed despite economic data, and vaccine rollouts - Wednesday Review, February 24

Stocks mixed despite economic data, and vaccine rollouts - Wednesday Review, February 24

Most markets gained momentum amid expectations of a new fiscal aid

The US

Stocks closed higher as expectations for a new fiscal stimulus and progress made with the COVID-19 vaccine rollout could potentially lead to a more robust economic recovery. USA30 rose 1.4%, closing at a record high. USA500 added 1.1%, and TECH100 gained 0.99%.

Crude oil lost 0.5% reaching $61.38 per barrel.

Gold settled at $1,805.90 per ounce.

Asia and Australia

Markets were lower even though the US Federal Reserve pledged to continue its support for recovery from COVID-19, and their American peers closed at a record high.

Japan225 fell 0.93%.

HongKong45 slumped 2.36%.

Down under, Australia200 closed 1.05% lower.


Stocks traded in a mixed manner, as Germany's economic data showed that its economy grew stronger-than-expected at the end of 2020. Germany30 gained 0.4%. UK100 was down 0.7%, and France40 fell 0.1%.

Brent oil closed 0.2% lower at $64.35 per barrel.

EUR/USD traded at 1.2167 after it went up 0.2%.


This information prepared by is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.

Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of